G Ferrandina

Summary

Country: Italy

Publications

  1. doi request reprint Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University, Rome, Italy
    Gynecol Oncol 128:518-23. 2013
  2. doi request reprint Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Rome, Italy
    Ann Surg Oncol 21:1692-9. 2014
  3. pmc MiR-200c and HuR in ovarian cancer
    Silvia Prislei
    Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome 00168, Italy
    BMC Cancer 13:72. 2013
  4. doi request reprint Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 130:505-10. 2013
  5. pmc Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
    Giovanna Mantegna
    Psycho Oncology Service, Catholic University, Campobasso, Italy
    BMC Cancer 13:127. 2013
  6. pmc Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report
    Maddalena Borriello
    Department of Oncology, Gynecologic Oncology Unit, Catholic University, Campobasso, Italy
    Diagn Pathol 7:116. 2012
  7. ncbi request reprint Novel VEGF-independent strategies targeting tumor vasculature: clinical aspects
    Marco Petrillo
    Department of Oncology, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy
    Curr Pharm Des 18:2702-12. 2012
  8. doi request reprint Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy
    Gynecol Oncol 124:389-94. 2012
  9. doi request reprint Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: impact on outcome and treatment-related complications
    G Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy Gynecologic Oncology Unit, Catholic University, Rome, Italy
    Eur J Surg Oncol 38:238-44. 2012
  10. doi request reprint Novel targets for VEGF-independent anti-angiogenic drugs
    Marco Petrillo
    Catholic University of the Sacred Heart, Gynecologic Oncology Unit, Department of Oncology, Campobasso, Italy
    Expert Opin Investig Drugs 21:451-72. 2012

Collaborators

Detail Information

Publications149 found, 100 shown here

  1. doi request reprint Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University, Rome, Italy
    Gynecol Oncol 128:518-23. 2013
    ..Progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis to recurrence/progression of disease or death, respectively...
  2. doi request reprint Completion surgery after concomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Rome, Italy
    Ann Surg Oncol 21:1692-9. 2014
    ....
  3. pmc MiR-200c and HuR in ovarian cancer
    Silvia Prislei
    Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome 00168, Italy
    BMC Cancer 13:72. 2013
    ..This study assessed the role of miR-200c as regulator of class III β-tubulin (TUBB3), a factor associated with drug-resistance and poor prognosis in ovarian cancer...
  4. doi request reprint Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 130:505-10. 2013
    ..The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis) in very heavily treated, relapsed ovarian cancer (ROC) patients...
  5. pmc Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
    Giovanna Mantegna
    Psycho Oncology Service, Catholic University, Campobasso, Italy
    BMC Cancer 13:127. 2013
    ..Here, we provide the first 2-years prospective, longitudinal study evaluating emotional distress and QoL in early stage (ECC) and locally advanced (LACC) cervical cancer patients who remained disease-free 2-years from diagnosis...
  6. pmc Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report
    Maddalena Borriello
    Department of Oncology, Gynecologic Oncology Unit, Catholic University, Campobasso, Italy
    Diagn Pathol 7:116. 2012
    ..Here, we report a case of liposarcomatous transformation of Madelung's disease in a 59-year-old Italian woman with a coincidental diagnosis of breast cancer...
  7. ncbi request reprint Novel VEGF-independent strategies targeting tumor vasculature: clinical aspects
    Marco Petrillo
    Department of Oncology, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy
    Curr Pharm Des 18:2702-12. 2012
    ....
  8. doi request reprint Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy
    Gynecol Oncol 124:389-94. 2012
    ....
  9. doi request reprint Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: impact on outcome and treatment-related complications
    G Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy Gynecologic Oncology Unit, Catholic University, Rome, Italy
    Eur J Surg Oncol 38:238-44. 2012
    ..The study aimed at describing the prevalence, and pattern of comorbidities, as well as their clinical role in a large series of locally advanced cervical cancer (LACC) patients triaged to preoperative chemoradiation...
  10. doi request reprint Novel targets for VEGF-independent anti-angiogenic drugs
    Marco Petrillo
    Catholic University of the Sacred Heart, Gynecologic Oncology Unit, Department of Oncology, Campobasso, Italy
    Expert Opin Investig Drugs 21:451-72. 2012
    ....
  11. pmc Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literature
    Marco Petrillo
    Department of Oncology, Catholic University, Campobasso, Italy
    Diagn Pathol 6:95. 2011
    ..A revision of the currently published cases have been also provided...
  12. pmc Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report
    Giacomo Corrado
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, L, go A, Gemelli, 1 86100, Campobasso Italy
    Diagn Pathol 5:29. 2010
    ..We report the first case of isolated pancreatic lymph node recurrence in a locally advanced breast cancer patient...
  13. pmc Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
    Francesco Legge
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy
    BMC Cancer 11:214. 2011
    ..We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients...
  14. pmc Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    BMC Cancer 8:252. 2008
    ..The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer...
  15. pmc Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
    Francesco Legge
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of Campobasso, Italy
    BMC Cancer 8:367. 2008
    ..The aim of the study was to retrospectively review ILNR observed in our Institution over the past 11 years in order to investigate: the pattern of disease progression after the first diagnosis of ILNR, and their clinical outcome...
  16. ncbi request reprint Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University, Rome, Italy
    Gynecol Oncol 104:326-30. 2007
    ....
  17. ncbi request reprint Lymph node involvement in locally advanced cervical cancer patients administered preoperative chemoradiation versus chemotherapy
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, L go A Gemelli 8, 00168, Rome, Italy
    Ann Surg Oncol 14:1129-35. 2007
    ..Finally, we investigated whether the pathologically assessed status of lower pelvic nodes (LPN) was able to predict the pathologically assessed status of upper pelvic nodes (UPN) and parametrium in cases administered CT/RT...
  18. ncbi request reprint Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 103:500-5. 2006
    ....
  19. pmc Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University, L go Gemelli 8, 00168, Rome, Italy
    BMC Cancer 6:169. 2006
    ..The occurrence of skeletal muscle metastases is a very rare event. Only two cases of late skeletal muscle recurrence from cervical cancer have been documented until now...
  20. pmc Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University, L, go Gemelli 8, 00168, Rome, Italy
    BMC Cancer 6:182. 2006
    ..To our knowledge, no data has been reported until now about the association between COX-2 status and response to different chemotherapy regimens...
  21. ncbi request reprint Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations
    Gabriella Ferrandina
    Gynaecologic Oncology Unit, Catholic University of Rome, L go A Gemelli 8, 00168 Rome, Italy
    Eur J Cancer 42:2296-302. 2006
    ..Duration of PFI and type of recurrence may independently influence post-relapse survival in ovarian cancer patients...
  22. ncbi request reprint Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Italy
    Clin Cancer Res 12:2774-9. 2006
    ..We also investigated whether beta III tubulin expression could be modified after the selective pressure represented by chemotherapy in vivo...
  23. ncbi request reprint Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Histology, Catholic University of Rome, Rome, Italy
    Clin Cancer Res 12:2055-60. 2006
    ..Circulating levels of cytokines [interleukin (IL)-1beta, IL-10, tumor necrosis factor-alpha, IL-6, and IL-12] and angiogenesis-modulating factors (vascular endothelial growth factor and endostatin) have also been analyzed...
  24. ncbi request reprint Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 99:215-7. 2005
    ..We describe a case of conservatively treated endometrial endometrioid (EE) adenocarcinoma which showed an aggressive clinical outcome after pregnancy...
  25. ncbi request reprint Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
    Gynecol Oncol 98:383-9. 2005
    ..The simultaneous assessment of p53 protein, ki67, and neu protein has been carried out...
  26. ncbi request reprint Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, L go A Gemelli, 8 00168 Rome, Italy
    Gynecol Oncol 98:267-73. 2005
    ..The combination of GEM/PLD has been tested for its efficacy on survival of recurrent ovarian cancer patients...
  27. ncbi request reprint Skull metastasis in primary vulvar adenocarcinoma of the Bartholin's gland: a case report
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 98:322-4. 2005
    ..Metastatic bone involvement in vulvar squamous carcinoma is very rare. Here, we present a case of primary adenocarcinoma of the Bartholin's gland giving rise to isolated skull metastasis...
  28. ncbi request reprint Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Contrada Tappino, Campobasso, Italy
    Gynecol Oncol 108:220-5. 2008
    ..The aim of the study was to analyze the accuracy of pelvic lymph node frozen section examination in a large, consecutive series of locally advanced cervical cancer (LACC) patients undergoing preoperative CT/RT...
  29. pmc Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Largo A Gemelli, 8, 00168 Rome, Italy
    Br J Cancer 92:271-7. 2005
    ..A more in depth investigation of the complex physiology of divergent survivin variants is needed in order to clarify the biological and the clinical role of differentially located survivin isoforms...
  30. ncbi request reprint Cyclooxygenase-2 expression in borderline ovarian tumors
    Gabriella Ferrandina
    Department of Obstetrics and Gynecology, Catholic University, 00168 Rome, Italy
    Gynecol Oncol 95:46-51. 2004
    ..Moreover, to perform a comparative analysis, COX-2 expression was also analyzed in benign and malignant ovarian tumors...
  31. ncbi request reprint Serous ovarian carcinoma recurring as a heterologous carcinosarcoma
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy
    J Obstet Gynaecol Res 33:95-9. 2007
    ..The immunohistochemical analysis of several biological parameters in primary ovarian adenocarcinoma and recurrent carcinosarcoma has been also performed...
  32. ncbi request reprint Glassy cell carcinoma of the endometrium: a case report and review of the literature
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University, L go A Gemelli 8, 00168 Rome, Italy
    Pathol Res Pract 203:217-20. 2007
    ....
  33. ncbi request reprint A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, L go A Gemelli 8, 00168 Rome, Italy
    Cancer Chemother Pharmacol 60:459-61. 2007
    ..Gemcitabine (2',2'-difluorodeoxycytidine) (GEM) has been demonstrated to be active in the salvage setting of ovarian cancer (OC) patients...
  34. doi request reprint Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy
    Gynecol Oncol 119:404-10. 2010
    ..The study aims at analyzing the long-term results of this multimodal approach in a single institution series of 184 cases...
  35. pmc Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
    G Ferrandina
    Gynecologic Oncology Unit, Division of Gynecologic Oncology, Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Italy
    Br J Cancer 101:1066-73. 2009
    ..This large, prospective study aims at investigating the role of computed tomography (CT) scan in predicting the feasibility of optimal cytoreduction in ovarian cancer...
  36. doi request reprint Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Italy
    Cancer Chemother Pharmacol 65:679-86. 2010
    ..The aim of the study is to investigate the potential clinical role of hENT1, hCNT1, dCK, RRM1, RRM2, CDA, and 5'NT in a single institutional series of 25 primary ovarian carcinomas...
  37. pmc CD133 antigen expression in ovarian cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy
    BMC Cancer 9:221. 2009
    ..The aim of the study was to investigate the clinical role of the immunohistochemically assessed expression of CD133 in a large single Institution series of ovarian cancer patients...
  38. doi request reprint Targeting CD133 antigen in cancer
    Gabriella Ferrandina
    Catholic University, Gynecologic Oncology Unit, L go A Gemelli 1, 86100 Campobasso, Italy
    Expert Opin Ther Targets 13:823-37. 2009
    ..On the basis of the involvement of CSCs in tumourigenesis and treatment resistance, it is conceivable that only eradication of CSCs can lead to a cancer cure...
  39. pmc Conservatively treated glassy cell carcinoma of the cervix
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Rome, Italy
    World J Surg Oncol 6:92. 2008
    ..Very little data about the conservative treatment of early stage glassy cell cervical cancer have been reported...
  40. doi request reprint Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy
    Oncology 74:42-9. 2008
    ....
  41. pmc Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients
    G Ferrandina
    Department of Oncology, Catholic University, Campobasso, Italy
    Br J Cancer 98:1910-5. 2008
    ..Our study suggests that the assessment of TOPO-IIalpha could be helpful to identify poor prognosis platinum-resistant ovarian cancer patients, potentially candidates to investigational agents...
  42. doi request reprint Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer
    Gabriella Ferrandina
    Department of Oncology, Catholic University of Campobasso, Italy
    Gynecol Oncol 109:187-93. 2008
    ....
  43. doi request reprint Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
    Gabriella Ferrandina
    Department of Oncology, Catholic University, Campobasso, Italy
    J Clin Oncol 26:890-6. 2008
    ..We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with pegylated liposomal doxorubicin (PLD) in the salvage treatment of recurrent ovarian cancer...
  44. doi request reprint A case of isolated ovarian recurrence from vulvar carcinoma
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University of the Sacred Heart, Largo A Gemelli, 1, 86100 Campobasso, Italy
    Arch Gynecol Obstet 278:393-6. 2008
    ..This observation expands the range of unusual clinical presentations of recurrence sites from vulvar carcinoma, and emphasizes the need not to underestimate the role of long complete follow-up program in vulvar cancer patients...
  45. ncbi request reprint Expression of CD133-1 and CD133-2 in ovarian cancer
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy
    Int J Gynecol Cancer 18:506-14. 2008
    ..CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential...
  46. ncbi request reprint Endometrial carcinoma recurring as carcinosarcoma: report of two cases
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Pathol Res Pract 203:677-81. 2007
    ....
  47. ncbi request reprint Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy
    Ann Oncol 18:1348-53. 2007
    ..A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months...
  48. doi request reprint Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy
    Cancer 118:392-403. 2012
    ....
  49. doi request reprint Hospital costs incurred by the Italian National Health Service for invasive cervical cancer
    Gabriella Ferrandina
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy
    Gynecol Oncol 119:243-9. 2010
    ..Costs were estimated using DRG charges. All patients with histological diagnosis of invasive cervical cancer admitted to Gynecologic Oncology centres of the Catholic University of the Sacred Heart between 2000 and 2007 were enrolled...
  50. ncbi request reprint Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Ann Oncol 13:1205-11. 2002
    ..The aim of this study was to investigate the expression of COX-2 and its association with clinicopathological parameters, response to treatment, and clinical outcome in ovarian cancer patients...
  51. ncbi request reprint Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    J Clin Oncol 20:973-81. 2002
    ..To investigate the expression of cyclooxygenase (COX-2) and its association with clinicopathologic parameters and clinical outcome in patients with cervical cancer...
  52. doi request reprint Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors
    M Petrillo
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome
    Gynecol Oncol 131:36-41. 2013
    ..We evaluated the clinical outcome and prognostic factors for post-relapse survival (PRS) in a large retrospective series of ovarian cancer patients with localized relapse...
  53. ncbi request reprint Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer
    S Greggi
    Department of Obstetrics/Gynaecology, Catholic University of the Sacred Heart, Rome, Italy
    Oncology 60:19-23. 2001
    ..5%; 95% CI: 18-56.8) and 12 progressions (50%; 95% CI: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately...
  54. pmc Prognostic significance of methyl-p-hydroxy-phenyllactate-esterase activity in laryngeal squamous cell carcinoma
    M Maurizi
    Institute of Otolaryngology, Catholic University, Rome, Italy
    Br J Cancer 77:1253-9. 1998
    ..On multivariate analysis, both EGFR and MeHPLAase activity proved to be independent factors for predicting a short relapse and the overall survival...
  55. ncbi request reprint Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma
    S Fiumicino
    Laboratory of Comparative Toxicology and Ecotoxicology, , Rome, Italy
    J Clin Oncol 19:1008-14. 2001
    ..CONCLUSION: The assessment of microsatellite status may provide useful information for preoperative prognostic characterization of stage I-II primary sporadic EEA patients in which more individualized treatment options can be attempted...
  56. pmc Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo F Vito, I 00168 Rome, Italy
    Br J Cancer 87:1145-52. 2002
    ....
  57. doi request reprint Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiation
    F Fanfani
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, L go A Gemelli 8, 00168 Rome, Italy Electronic address
    Eur J Surg Oncol 39:1025-9. 2013
    ..To evaluate the feasibility and the predictive value of cone biopsy before performing radical hysterectomy in locally advanced cervical cancer patients showing complete clinical response to neo-adjuvant chemoradiation...
  58. doi request reprint Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: a prospective study
    A C Testa
    Department of Obstetrics Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Ultrasound Obstet Gynecol 39:99-105. 2012
    ..To analyze in advanced ovarian cancer patients the ability of ultrasound to evaluate the extent of intra-abdominal disease and to predict the likelihood of suboptimal cytoreduction...
  59. ncbi request reprint Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progeni
    A Fattorossi
    Department of Obstetrics and Gynecology, Universita Cattolica del Sacro Cuore, Rome, Italy
    Cancer Immunol Immunother 49:641-8. 2001
    ..The up-modulation of Fcgamma receptor II was maintained until day 40. Thus, administering G-CSF and GM-CSF in the post-transplant period affects T lymphocyte proliferation and phagocyte membrane molecules differently...
  60. pmc Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
    M Maurizi
    Department of Otolaryngology, Catholic University, Rome, Italy
    Br J Cancer 74:1253-7. 1996
    ..In this study we demonstrated that high EGFR levels single out patients with poor prognosis in laryngeal cancer...
  61. ncbi request reprint Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor
    G Scambia
    Department of Gynecology, Catholic University, Rome, Italy
    Am J Obstet Gynecol 168:71-8. 1993
    ..The aim of the study was to investigate the biologic significance of p21 expression in normal and neoplastic ovarian tissues...
  62. ncbi request reprint Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Int J Radiat Oncol Biol Phys 55:21-7. 2003
    ..To investigate whether cyclooxygenase-2 (COX-2) could be a marker of clinical outcome in cervical cancer patients undergoing concomitant chemoradiation plus surgery...
  63. pmc Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
    C Ferlini
    Laboratory of Antineoplastic Pharmacology, Zeneca, Rome, Italy
    Br J Cancer 79:257-63. 1999
    ..Importantly, the induction of apoptosis by TAM is not linked to down-regulation or functional inactivation by phosphorylation of the antiapoptotic bcl-2 protein...
  64. pmc Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy
    G Scambia
    Department of Gynecology and Obstetrics, Catholic University, Rome, Italy
    Br J Cancer 72:361-6. 1995
    ..0033), patient survival was not related to steroid hormone receptor status. Among the parameters tested only stage, ascites and EGFR status retained an independent prognostic value in the multivariate analysis...
  65. pmc hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer
    A Ercoli
    Department of Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Br J Cancer 80:1665-71. 1999
    ..Our study suggests a possible involvement of hMSH2 in ovarian cancer cell biology and susceptibility to chemotherapy. The possible biological and/or clinical role of GTBP expression in ovarian cancer patients remains to be elucidated...
  66. ncbi request reprint Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
    D Lorusso
    Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Italy
    Oncology 67:243-9. 2004
    ..The aim of this study was to investigate whether a different treatment schedule may improve the toxicity profile, especially in terms of dermatological and mucosal toxicity...
  67. ncbi request reprint Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse
    G Almadori
    Institute of Otorhinolaryngology, Catholic University of the Sacred Heart, Rome, Italy
    Int J Cancer 84:188-91. 1999
    ..Our results suggest that the assessment of EGFR status at the time of diagnosis may identify a subset of LSCC patients highly susceptible to neck node metastases thus defining therapy accordingly...
  68. ncbi request reprint Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo A Gemelli 8, 00168 Rome, Italy
    Gynecol Oncol 85:305-10. 2002
    ..The involvement of COX-2 in ErbB family pathways has been proposed. We investigated by immunohistochemistry the expression of COX-2, EGFR, and Her-2/neu in a series of advanced primary ovarian cancers...
  69. ncbi request reprint Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall
    G Corrado
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy
    J Chemother 23:49-52. 2011
    ..Our case demonstrates that a multimodal approach in patients with chest wall recurrence of breast cancer without distant metastasis, may be safe and effective for maintaining a good quality of life...
  70. pmc Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
    G Ferrandina
    Department of Gynecology Oncology, Catholic University of the Sacred Heart, Largo A Gemelli, Rome 00168, Italy
    Br J Cancer 89:1180-4. 2003
    ..Grade 3-4 hematological toxicity was registered in 30 patients (42.8%), mainly represented by neutropenia (35.6%); palmar-plantar erythrodysesthesia affected 24 patients (34.2%), but it was of grade 3 in only seven of them (10%)...
  71. pmc p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
    G Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Br J Cancer 81:733-40. 1999
    ..Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients...
  72. ncbi request reprint Is there a place for a less extensive radical surgery in locally advanced cervical cancer patients?
    G Scambia
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, 00168, Italy
    Gynecol Oncol 83:319-24. 2001
    ..A series of 29 early cervical cancer patients was also included in the analysis...
  73. ncbi request reprint Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures
    G Ferrandina
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy
    Gynecol Oncol 107:S127-32. 2007
    ..To evaluate the morbidity, and the therapeutic value of surgery after chemoradiation in a large series of locally advanced cervical cancers (LACC). The prognostic role of different clinico-pathological factors has been also evaluated...
  74. pmc Nm23 expression in endometrial and cervical cancer: inverse correlation with lymph node involvement and myometrial invasion
    M Marone
    Department of Obstetrics and Gynaecology, Catholic University, Rome, Italy
    Br J Cancer 74:1063-8. 1996
    ..003). Nm23 level may therefore be taken into consideration as a new marker in the prognostic characterisation and in the treatment planning of uterine tumour patients...
  75. pmc Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells
    G Scambia
    Department of Gynaecology, Catholic University, Rome, Italy
    Br J Cancer 62:942-6. 1990
    ..Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a binding interaction with type II EBS. This mechanism could also be active in vivo since primary ovarian tumours contain type II EBS...
  76. ncbi request reprint Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility
    Mariagrazia Distefano
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Oncology 67:103-11. 2004
    ..We also investigated the role of cyclooxygenase-2 (COX-2) in this clinical setting...
  77. ncbi request reprint Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients
    R Giannice
    Department of Gynecology, Catholic University of the Sacred Heart of Rome, Rome, Italy
    Cancer 92:2562-8. 2001
    ..Advanced chronologic age alone should not be considered a contraindication to full surgical treatment in these patients...
  78. ncbi request reprint Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer
    G Ferrandina
    Department of Gynecology/Obstetrics, Catholic University of Rome, Italy
    Clin Cancer Res 7:2656-61. 2001
    ....
  79. doi request reprint Sonographic features of primary ovarian fibrosarcoma: a report of two cases
    A C Testa
    Gynecologic Oncology Unit, Catholic University of Rome, Rome, Italy
    Ultrasound Obstet Gynecol 33:112-5. 2009
    ..We speculate that ovarian fibrosarcoma at the preoperative examination might be considered in the differential diagnosis whenever a unilateral, heterogeneous, largely round solid ovarian lesion is detected...
  80. doi request reprint Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?
    A Fagotti
    Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy
    Gynecol Oncol 116:72-7. 2010
    ..Secondary: To identify the most appropriate level of laparoscopic index value (PIV) to identify inoperable patients in this subset of patients...
  81. doi request reprint Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer
    A C Testa
    Gynecologic Oncology Unit, Catholic University of the Sacred Heart, L go A Gemelli 8, Rome 00168, Italy
    Ultrasound Obstet Gynecol 34:335-44. 2009
    ....
  82. ncbi request reprint Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives
    D Lorusso
    Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Italy
    Int J Gynecol Cancer 15:1002-13. 2005
    ..Further combination of gemcitabine and other agents, including paclitaxel, is also feasible and has been actively studied in order to establish the role of gemcitabine in the management of treated and untreated ovarian cancer patients...
  83. ncbi request reprint High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results
    M G Salerno
    Department of Gynecology, Catholic University of Rome, Rome, Italy
    Bone Marrow Transplant 27:1017-25. 2001
    ..Patients who underwent IDS because of unresectable tumors at the time of first surgery had the greater survival benefit from HDC...
  84. ncbi request reprint Does quantitative analysis of three-dimensional power Doppler angiography have a role in the diagnosis of malignant pelvic solid tumors? A preliminary study
    A C Testa
    Department of Gynecology, Catholic University, Rome, Italy
    Ultrasound Obstet Gynecol 26:67-72. 2005
    ..To investigate the role of a simplified method for the three-dimensional (3D) quantification of tumor vascularity in the differential diagnosis of solid pelvic masses...
  85. ncbi request reprint Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study
    Gabriella Ferrandina
    Department of Gynecology Obstetrics, Catholic University of the Sacred Heart, 00168 Rome, Italy
    Clin Cancer Res 9:4324-31. 2003
    ..Serum levels of squamous cell carcinoma antigen and the proliferative potential and subsets of peripheral T cells before and after celecoxib treatment were also analyzed...
  86. doi request reprint Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1)
    Gabriella Macchia
    Radiotherapy Unit, Department of Oncology, John Paul II Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Largo A Gemelli 1, Campobasso, Italy
    Gynecol Oncol 118:128-33. 2010
    ..To determine the recommended preoperative dose of large-field chemoradiation along with concomitant boost dose escalation on the tumor in locally advanced cervical carcinoma (LACC)...
  87. ncbi request reprint Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome
    Daniela Smaniotto
    Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, Italy
    Tumori 91:295-301. 2005
    ....
  88. ncbi request reprint Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients
    Simona Mozzetti
    Laboratory of Antineoplastic Pharmacology, Universita Cattolica Sacro Cuore, Rome, Italy
    Clin Cancer Res 11:298-305. 2005
    ..By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III beta-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer...
  89. ncbi request reprint Concurrent 5-fluorouracil, mitomycin C and radiation, with or without brachytherapy, in recurrent endometrial cancer: a scoring system to predict clinical response and outcome
    Daniela Smaniotto
    Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, Italy
    Tumori 91:215-20. 2005
    ....
  90. ncbi request reprint Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer
    Giuseppe D'Agostino
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Oncology 62:110-4. 2002
    ..7%; 95% confidence interval, CI: 4.9-38.5), 5 disease stabilizations (21.7%, 95% CI: 4.9-38.5) and 13 progressions (56.6%, 95% CI: 36.4-76.8) have been registered. These results warrant further research in a phase II study...
  91. ncbi request reprint Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma
    Andrea Fattorossi
    Unità operativa assistenziale di Ginecologia Oncologica, Istituto di Ginecologia, Universita Cattolica S Cuore, Rome, Italy
    Cancer 100:1418-28. 2004
    ..The objective of the current study was to illustrate the influence of neoadjuvant therapy on the local immune response in patients with cervical carcinoma...
  92. ncbi request reprint Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer
    Gabriella Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Clin Cancer Res 10:3117-23. 2004
    ..The aim of this study was to analyze the clinical role of cyclooxygenase (COX)-2 in a large series of 175 cervical cancer patients...
  93. ncbi request reprint Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin
    Giuseppe D'Agostino
    Department of Gynaecology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy
    Cancer Chemother Pharmacol 49:256-60. 2002
    ....
  94. doi request reprint Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome
    Francesco Fanfani
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 1, Rome, Italy
    Int J Gynecol Cancer 19:1119-24. 2009
    ..To demonstrate the efficacy and feasibility of preoperative chemoradiation followed by radical surgery in a consecutive series of patients with stage IIIB cervical cancer...
  95. pmc Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer
    Alessandra Battaglia
    Gynecologic Oncology Unit, Universita Cattolica S Cuore, Campobasso, Italy
    Immunology 123:129-38. 2008
    ....
  96. ncbi request reprint Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer
    A Ercoli
    Department of Gynecology, Catholic University, Rome, Italy
    Int J Gynecol Cancer 15:308-11. 2005
    ..Moreover, cisplatin exposure did not seem to select for MMR-deficient tumor clones in cervical cancer...
  97. doi request reprint Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
    D Lorusso
    Department of Gynaecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, IT 00168 Rome, Italy
    Ann Oncol 21:61-6. 2010
    ..The objective of the study was to estimate the antitumor activity of pemetrexed in patients with advanced/recurrent carcinoma of the cervix and to determine the nature and degree of toxicity...
  98. ncbi request reprint Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center
    F Legge
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 104:551-6. 2007
    ..The possible clinical benefit to patients resulting from the participation in these trials has been also investigated...
  99. doi request reprint Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity
    Domenica Lorusso
    Catholic University of the Sacred Heart, Department of Gynecologic Oncology, Rome, Italy
    Expert Opin Investig Drugs 18:1939-46. 2009
    ..Preliminary results of activity and toxicities of brostallicin in Phase I and II studies will be provided...
  100. ncbi request reprint Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome
    Gabriella Ferrandina
    Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
    Cancer 95:801-7. 2002
    ..The relationship between COX-2 expression and microsatellite instability (MI) status was also analyzed...
  101. doi request reprint Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma
    Anna Fagotti
    Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy
    Am J Obstet Gynecol 199:642.e1-6. 2008
    ..The purpose of this study was to validate the performance of a laparoscopy-based model to predict optimal cytoreduction in advanced ovarian cancer patients...